Journal of comparative effectiveness research
-
Meta Analysis Comparative Study
An indirect comparison of ustekinumab and vedolizumab in the therapy of TNF-failure Crohn's disease patients.
An indirect comparison of ustekinumab versus vedolizumab in patients with active moderate-to-severe Crohn's disease who were nonresponsive or intolerant to previous TNF-antagonist therapy. ⋯ No significant differences between vedolizumab and ustekinumab in clinical response and clinical remission for induction and remission in maintenance phase of TNF refractory patients therapy were revealed. In addition, no significant disparities in the risk of adverse events suggest a similar safety profile.